Payment overview · 2025
General Payments
$1,181.38
44 reported records · 15 companies
Healthcare provider profile · identity verified
John Sauret, MD
Allopathic & Osteopathic Physicians|Family Medicine · NIAGARA FALLS, NY · NPI 1225000268
Verified facts
What the public records show
CMS Open Payments records show John Sauret, MD received $1,181.38 in general payments during 2025 across 44 reported records.
AstraZeneca Pharmaceuticals LP accounted for 28.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 22 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Ozempic, Trelegy Ellipta.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 79 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $331.56 | 28.1% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $180.83 | 15.3% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $145.16 | 12.3% | 8 | 2025 |
| SHIELD THERAPEUTICS INC | Unresolved — no canonical attribution shown | $77.50 | 6.6% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $73.44 | 6.2% | 4 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $70.42 | 6.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $50.80 | 4.3% | 3 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $46.48 | 3.9% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.00 | 3.3% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.50 | 2.8% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.29 | 2.8% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.22 | 2.5% | 2 | 2025 |
| Metacel Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $27.09 | 2.3% | 1 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $26.99 | 2.3% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $16.10 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,181.38 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $307.01 | 3 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $190.46 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $180.83 | 4 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $108.97 | 6 | 2025 |
Source payment records
|
|||||
| ACCRUFER Normalized: accrufer |
Drug | SHIELD THERAPEUTICS INC | $77.50 | 5 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $70.42 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $58.07 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $49.60 | 3 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $46.48 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.00 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $35.36 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $35.36 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $33.50 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.29 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.29 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $29.22 | 2 | 2025 |
Source payment records
|
|||||
| OZOBAX Normalized: ozobax |
Drug | Metacel Pharmaceuticals LLC | $27.09 | 1 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $26.99 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $17.44 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $12.65 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 117 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 79 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
80 | 16 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
117 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
79 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
74 | 17 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
117 | 23 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 710 | 144 |
| Atorvastatin Calcium | Atorvastatin Calcium | 590 | 135 |
| Lisinopril | Lisinopril | 402 | 84 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 336 | 77 |
| Gabapentin | Gabapentin | 299 | 55 |
| Hydrochlorothiazide | Hydrochlorothiazide | 245 | 47 |
| Metformin Hcl | Metformin Hcl | 236 | 53 |
| Pantoprazole Sodium | Pantoprazole Sodium | 220 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 219 | 65 |
| Omeprazole | Omeprazole | 196 | 31 |
| Levothyroxine Sodium | Levothyroxine Sodium | 182 | 42 |
| Metoprolol Succinate | Metoprolol Succinate | 169 | 33 |
| Famotidine | Famotidine | 167 | 36 |
| Potassium Chloride | Potassium Chloride | 159 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 159 | 28 |
| Hydralazine Hcl | Hydralazine Hcl | 139 | 32 |
| Furosemide | Furosemide | 134 | 23 |
| Pregabalin | Pregabalin | 133 | 18 |
| Ibuprofen | Ibuprofen | 128 | 29 |
| Glipizide | Glipizide | 126 | 26 |
| Trazodone Hcl | Trazodone Hcl | 119 | 25 |
| Eliquis | Apixaban | 117 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 27 |
| Clopidogrel | Clopidogrel Bisulfate | 103 | 19 |
| Duloxetine Hcl | Duloxetine Hcl | 91 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 90 | 25 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 89 | 17 |
| Meloxicam | Meloxicam | 82 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 80 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 79 | 13 |
| Trulicity | Dulaglutide | 74 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 73 | 11 |
| Azithromycin | Azithromycin | 72 | 48 |
| Tamsulosin Hcl | Tamsulosin Hcl | 71 | 14 |
| Carvedilol | Carvedilol | 70 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 70 | 18 |
| Bumetanide | Bumetanide | 67 | 11 |
| Warfarin Sodium | Warfarin Sodium | 66 | suppressed |
| Synthroid | Levothyroxine Sodium | 65 | 11 |
| Baclofen | Baclofen | 63 | suppressed |
| Ezetimibe | Ezetimibe | 63 | 13 |
| Sertraline Hcl | Sertraline Hcl | 63 | 16 |
| Losartan Potassium | Losartan Potassium | 56 | 16 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 12 |
| Buspirone Hcl | Buspirone Hcl | 52 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 13 |
| Montelukast Sodium | Montelukast Sodium | 46 | suppressed |
| Allopurinol | Allopurinol | 45 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 45 | 11 |
| Jardiance | Empagliflozin | 44 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 41 | suppressed |
| Levetiracetam | Levetiracetam | 40 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 40 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 39 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 37 | suppressed |
| Tradjenta | Linagliptin | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | 11 |
| Simvastatin | Simvastatin | 33 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 32 | suppressed |
| Linzess | Linaclotide | 30 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 27 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Lovastatin | Lovastatin | 27 | suppressed |
| Bupropion Xl | Bupropion Hcl | 26 | suppressed |
| Spironolactone | Spironolactone | 26 | suppressed |
| Clotrimazole | Clotrimazole | 24 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Nystatin | Nystatin | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 23 | 23 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Glimepiride | Glimepiride | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 22 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 21 | suppressed |
| Vascepa | Icosapent Ethyl | 21 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Gemfibrozil | Gemfibrozil | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | 14 |
| Alcohol Pads | Alcohol Antiseptic Pads | 18 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Niacin Er | Niacin | 18 | suppressed |
| Ozempic | Semaglutide | 18 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 17 | suppressed |
| Procto-Med Hc | Hydrocortisone | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 16 | suppressed |
| Mirtazapine | Mirtazapine | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 13 |
| Incruse Ellipta | Umeclidinium Bromide | 15 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 15 |
| Carbamazepine | Carbamazepine | 14 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Methylprednisolone | Methylprednisolone | 14 | 11 |
| Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 12 | suppressed |
| Ethosuximide | Ethosuximide | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Carbamazepine Er | Carbamazepine | 11 | suppressed |
| Famciclovir | Famciclovir | 11 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 11 | suppressed |
| Hydrocortisone | Hydrocortisone | 11 | suppressed |
| Lyrica | Pregabalin | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Nystop | Nystatin | 11 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,181.38 · 44 records | AstraZeneca Pharmaceuticals LP | ACCRUFER, AIRSUPRA, AREXVY, BREZTRI, Cologuard Collection Kit, ELIQUIS, FREESTYLE LIBRE 3, JARDIANCE, JOURNAVX, MOUNJARO, NURTEC ODT, OTEZLA, OZOBAX, Omnipod, Ozempic, REPATHA, Rybelsus, SHINGRIX, SUBLOCADE, TRELEGY ELLIPTA, VOQUEZNA, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error